{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T18:01:06Z","timestamp":1783360866595,"version":"3.54.6"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objectives<\/jats:title>\n<jats:p>Dyslipidemia is a prevalent condition with significant morbidity and mortality across the world, including in the Arabian Gulf. The present study aimed to describe the characteristics of patients receiving evolocumab in clinical practice.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>ZERBINI was a multi-country, observational, retrospective\/prospective study of subjects receiving evolocumab as part of routine clinical management of their hyperlipidemia. This regional publication reports on adult participants from Saudi Arabia and Kuwait who have had \u22651 dose of evolocumab before enrollment and \u22646 months\u2019 prior exposure to evolocumab. Patient characteristics and treatment persistence data were collected in addition to baseline and follow-up data up to 12 months post-evolocumab initiation.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Overall, 225 patients were included from two sites, Saudi Arabia (N = 155) and Kuwait (N = 70). Mean age was comparable across sites and most patients had baseline coronary artery disease and\/or hypertension. Baseline LDL-C levels (mean \u00b1 SD 3.6 \u00b1 1.4 mmol\/L in Saudi Arabia, 3.1 \u00b1 1.4 mmol\/L in Kuwait) were reduced by approximately 57%\u201362% in the first 6 months after evolocumab initiation (1.5 \u00b1 1.2 mmol\/L in Saudi Arabia [n = 63], 1.2 \u00b1 0.8 mmol\/L in Kuwait [n = 28]). This decrease was maintained over the 12-month follow-up period. Most patients achieved ACC 2018 LDL-C goals (&lt;1.8 mmol\/L; 74.6% in Saudi Arabia, 93.1% in Kuwait) and ESC 2019 LDL-C goals (&lt;1.4 mmol\/L; 66.7% in Saudi Arabia, 75.9% in Kuwait) in the first 6 months after evolocumab initiation. Medication persistence with evolocumab was high (up to 90.7%). Evolocumab had a favorable safety profile and no treatment-emergent adverse events were observed at either site.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Evolocumab is an effective lipid-lowering treatment in local populations. LDL-C goal achievement is increased when evolocumab is added to background lipid-lowering therapy with high tolerability and persistence. Long-term follow-up and large-scale data are needed to further support these observations.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0278821","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T18:37:49Z","timestamp":1674239869000},"page":"e0278821","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Multizonal observational study conducted by clinical practitioners on evolocumab use in subjects with hyperlipidemia in Saudi Arabia and Kuwait: Results from the ZERBINI study"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0237-9782","authenticated-orcid":true,"given":"Khalid","family":"Al Faraidy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mousa","family":"Akbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Shehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Aljarallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamal","family":"Abdin Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Dashti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Al Qudaimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Al Nouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuhier","family":"Awan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Essam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Emara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,1,20]]},"reference":[{"key":"pone.0278821.ref001","author":"WHO","year":"2021","journal-title":"Cardiovascular diseases (CVDs) [Internet]."},{"issue":"25","key":"pone.0278821.ref002","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global Burden of Cardiovascular Diseases and Risk Factors, 1990\u20132019: Update From the GBD 2019 Study.","volume":"76","author":"GA Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"SUPPL. 3","key":"pone.0278821.ref003","article-title":"Cardiovascular disease in the asia middle east region: Global trends and local implications.","volume":"22","author":"TM Ramahi","year":"2010","journal-title":"Asia-Pacific J Public Heal."},{"issue":"2","key":"pone.0278821.ref004","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrcardio.2017.138","article-title":"Cardiovascular disease in the Eastern Mediterranean region: epidemiology and risk factor burden.","volume":"15","author":"K Turk-Adawi","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"pone.0278821.ref005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/235101","article-title":"Prevalence of Cardiovascular Disease and Associated Risk Factors among Adult Population in the Gulf Region: A Systematic Review.","volume":"2015","author":"N Aljefree","year":"2015","journal-title":"Adv Public Heal."},{"key":"pone.0278821.ref006","unstructured":"WHO. Noncommunicable diseases: Risk factors [Internet]. Available from: https:\/\/www.who.int\/data\/gho\/data\/themes\/topics\/topic-details\/GHO\/ncd-risk-factors."},{"key":"pone.0278821.ref007","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.atherosclerosis.2021.11.022","article-title":"Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East: 2021 update","volume":"343","author":"N Alsayed","year":"2022","journal-title":"Atherosclerosis"},{"issue":"6","key":"pone.0278821.ref008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251560","article-title":"Familial Hypercholesterolemia in the Arabian Gulf Region: Clinical results of the Gulf FH Registry.","volume":"16","author":"KF Alhabib","year":"2021","journal-title":"PLoS One."},{"issue":"1","key":"pone.0278821.ref009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084350","article-title":"Results of the Dyslipidemia International Study (DYSIS)-Middle East: clinical perspective on the prevalence and characteristics of lipid abnormalities in the setting of chronic statin treatment.","volume":"9","author":"SN Al Sifri","year":"2014","journal-title":"PLoS One."},{"issue":"5","key":"pone.0278821.ref010","doi-asserted-by":"crossref","first-page":"552","DOI":"10.5551\/jat.31179","article-title":"Suboptimal Control of Lipid Levels: Results from 29 Countries Participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS).","volume":"23","author":"CE Chiang","year":"2016","journal-title":"J Atheroscler Thromb"},{"issue":"10263","key":"pone.0278821.ref011","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(20)32233-9","article-title":"Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70\u2013100 years: a contemporary primary prevention cohort","volume":"396","author":"MB Mortensen","year":"2020","journal-title":"Lancet (London, England)."},{"issue":"21","key":"pone.0278821.ref012","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1161\/CIRCULATIONAHA.118.034273","article-title":"Long-Term Association of Low-Density Lipoprotein Cholesterol with Cardiovascular Mortality in Individuals at Low 10-Year Risk of Atherosclerotic Cardiovascular Disease: Results from the Cooper Center Longitudinal Study","volume":"138","author":"SM Abdullah","year":"2018","journal-title":"Circulation"},{"issue":"20","key":"pone.0278821.ref013","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009778","article-title":"Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life.","volume":"7","author":"JG Robinson","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"32","key":"pone.0278821.ref014","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"BA Ference","year":"2017","journal-title":"Eur Heart J"},{"issue":"1","key":"pone.0278821.ref015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-020-01792-7","article-title":"LDL-C: Lower is better for longer\u2014Even at low risk.","volume":"18","author":"PE Penson","year":"2020","journal-title":"BMC Med."},{"issue":"10","key":"pone.0278821.ref016","article-title":"PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.","volume":"10","author":"AF Schmidt","year":"2020","journal-title":"Cochrane database Syst Rev."},{"issue":"6","key":"pone.0278821.ref017","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000014400","article-title":"Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia: A frequentist network meta-analysis.","volume":"98","author":"Z Zhao","year":"2019","journal-title":"Medicine (Baltimore)."},{"key":"pone.0278821.ref018","doi-asserted-by":"crossref","article-title":"Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 35 Randomized Controlled Trials.","author":"A Karatasakis","DOI":"10.1161\/JAHA.117.006910"},{"issue":"9","key":"pone.0278821.ref019","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1080\/03007995.2018.1477747","article-title":"A systematic literature review comparing methods for the measurement of patient persistence and adherence.","volume":"34","author":"CA Forbes","year":"2018","journal-title":"Curr Med Res Opin."},{"key":"pone.0278821.ref020","article-title":"Real-world Insights into Evolocumab Use in Patients with Hyperlipidemia: Canadian Analysis from the ZERBINI Study.","author":"M Gupta","year":"2022","journal-title":"CJC Open."},{"key":"pone.0278821.ref021","article-title":"A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia","volume":"2021","author":"X Ge","year":"2021","journal-title":"Biomed Res Int"},{"issue":"18","key":"pone.0278821.ref022","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"MS Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"9965","key":"pone.0278821.ref023","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.","volume":"385","author":"FJ Raal","year":"2015","journal-title":"Lancet"},{"issue":"Supplement_2","key":"pone.0278821.ref024","article-title":"Does Evolocumab use in Europe match 2019 ESC\/EAS lipid guidelines? Results from the HEYMANS study.","volume":"41","author":"K. Ray","year":"2020","journal-title":"Eur Heart J"},{"issue":"17","key":"pone.0278821.ref025","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1016\/j.jacc.2019.08.1024","article-title":"Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia","volume":"74","author":"MJ Koren","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"pone.0278821.ref026","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskThe Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS).","volume":"41","author":"F Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"25","key":"pone.0278821.ref027","first-page":"E1082","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"SM Grundy","year":"2019","journal-title":"Circulation"},{"issue":"4","key":"pone.0278821.ref028","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1007\/s12325-020-01259-4","article-title":"Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients at High Cardiovascular Risk: An Updated Systematic Review and Meta-Analysis of 32 Randomized Controlled Trials.","volume":"37","author":"G Mu","year":"2020","journal-title":"Adv Ther."},{"issue":"12","key":"pone.0278821.ref029","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1185\/03007995.2014.965774","article-title":"Therapeutic lipid target achievements among high and highest risk patients: results from the CEPHEUS study in the Arabian Gulf.","volume":"30","author":"K Al-Rasadi","year":"2014","journal-title":"Curr Med Res Opin."},{"issue":"2","key":"pone.0278821.ref030","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s41669-021-00300-8","article-title":"Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia.","volume":"6","author":"A Alghamdi","year":"2022","journal-title":"PharmacoEconomics\u2014open."},{"issue":"9","key":"pone.0278821.ref031","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.amjmed.2011.12.013","article-title":"Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients","volume":"125","author":"SH Naderi","year":"2012","journal-title":"Am J Med"},{"issue":"2","key":"pone.0278821.ref032","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s40119-021-00240-8","article-title":"Real-world Evidence for Adherence and Persistence with Atorvastatin Therapy.","volume":"10","author":"K Tsioufis","year":"2021","journal-title":"Cardiol Ther"},{"key":"pone.0278821.ref033","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.atherosclerosis.2018.12.026","article-title":"Adherence and persistence to hyperlipidemia medications in patients with atherosclerotic cardiovascular disease and those with diabetes mellitus based on administrative claims data in Japan","volume":"282","author":"M Wake","year":"2019","journal-title":"Atherosclerosis"},{"issue":"1","key":"pone.0278821.ref034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.120.016839","article-title":"Effects of Evolocumab on Low-Density Lipoprotein Cholesterol, Non-High Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a) by Race and Ethnicity: A Meta-Analysis of Individual Participant Data From Double-Blind and Open-Label Extension Studies.","volume":"10","author":"ML Daviglus","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"pone.0278821.ref035","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1001\/jamacardio.2017.0911","article-title":"Adherence to High-Intensity Statins Following a Myocardial Infarction Hospitalization Among Medicare Beneficiaries","volume":"2","author":"LD Colantonio","year":"2017","journal-title":"JAMA Cardiol"},{"key":"pone.0278821.ref036","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2017.05.018","article-title":"Effectiveness of adherence to lipid lowering therapy on LDL-cholesterol in patients with very high cardiovascular risk: A real-world evidence study in primary care","volume":"263","author":"V Guglielmi","year":"2017","journal-title":"Atherosclerosis"},{"issue":"2","key":"pone.0278821.ref037","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1093\/ijpp\/riab085","article-title":"Patient satisfaction with pharmaceutical care services for chronic diseases and their medication adherence during COVID-19 in Saudi Arabia","volume":"30","author":"JM Lucca","year":"2022","journal-title":"Int J Pharm Pract"},{"issue":"1","key":"pone.0278821.ref038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41983-021-00354-9","article-title":"Knowledge, attitudes, and impact of COVID-19 pandemic among neurology patients in Jordan: a cross-sectional study.","volume":"57","author":"M Athamneh","year":"2021","journal-title":"Egypt J Neurol Psychiatry Neurosurg"},{"issue":"11","key":"pone.0278821.ref039","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1111\/1756-185X.13960","article-title":"Impact of the COVID-19 pandemic on patients with chronic rheumatic diseases: A study in 15 Arab countries.","volume":"23","author":"N Ziad\u00e9","year":"2020","journal-title":"Int J Rheum Dis."},{"issue":"1","key":"pone.0278821.ref040","doi-asserted-by":"crossref","DOI":"10.1186\/s41927-021-00231-1","article-title":"The impact of COVID-19 on self-management behaviours and healthcare access for people with inflammatory arthritis.","volume":"5","author":"E Caton","year":"2021","journal-title":"BMC Rheumatol."},{"issue":"3","key":"pone.0278821.ref041","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ophtha.2021.10.009","article-title":"The Impact of the Coronavirus Disease 2019 Pandemic on Adherence to Ocular Hypotensive Medication in Patients with Primary Open-Angle Glaucoma.","volume":"129","author":"L Racette","year":"2022","journal-title":"Ophthalmology"},{"key":"pone.0278821.ref042","article-title":"Medication adherence in Medicare-enrolled older adults with asthma before and during the coronavirus disease 2019 pandemic.","author":"OL Ramey","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"pone.0278821.ref043","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1161\/CIRCOUTCOMES.120.006646","article-title":"Lipid Testing, Lipid-Modifying Therapy, and PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Eligibility in 27 979 Patients With Incident Acute Coronary Syndrome.","volume":"14","author":"B Sarak","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0278821","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T18:38:21Z","timestamp":1674239901000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0278821"}},"subtitle":[],"editor":[{"given":"Luigina","family":"Guasti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,1,20]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0278821","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,20]]}}}